HCPCS code J2506: Pegfilgrastim injection, per 0.5 mg2026 Medicare rate & RVUs in Missouri
Reports non-biosimilar pegfilgrastim administered to help prevent chemotherapy-related neutropenia, with each unit representing 0.5 mg of drug.
CMS doesn’t publish an office rate for J2506 in Missouri.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J2506 covers
J2506 represents non-biosimilar pegfilgrastim, a long-acting granulocyte colony-stimulating factor used to reduce the risk of infection associated with chemotherapy-related neutropenia. It is commonly given by subcutaneous injection after myelosuppressive cancer treatment. Oncology practices and hospital outpatient departments may report the drug when they furnish it; the code represents the medication, not the injection service. Neulasta is a familiar reference product for non-biosimilar pegfilgrastim.
CMS assigns physician fee schedule status E, excluding this drug from the physician fee schedule. When Medicare covers it, payment is through another method; the HCPCS pricing designation identifies it as a Part B drug generally priced from CMS quarterly ASP drug files. Coverage is left to the Medicare contractor’s judgment. One billing unit represents 0.5 mg, or 500 mcg, of pegfilgrastim. Report units based on the amount administered and retain documentation supporting the product and dose. Biosimilar pegfilgrastim products are reported with their applicable biosimilar codes, not J2506.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J2506 pays more and less in Missouri
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Kansas City, MO | Unavailable | Unavailable |
| Metropolitan St. Louis, MO | Unavailable | Unavailable |
| Rest of Missouri | Unavailable | Unavailable |
How the J2506 rate is calculated
Each of J2506’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J2506
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J2506
J2506 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J2506
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J2506 isn’t priced in this setting.
J2506 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- Q5108Fulphila injectionPer 0.5 mg
- Use Q5108 for pegfilgrastim-bmez, a biosimilar product. J2506 is for pegfilgrastim excluding biosimilars.
- Q5111Udenyca injectionPer 0.5 mg
- Use Q5111 for pegfilgrastim-cbqv, a biosimilar product; use J2506 for non-biosimilar pegfilgrastim.
- J1442Filgrastim injectionPer 1 microgram
- J1442 is filgrastim, a different G-CSF drug, reported per 1 mcg. J2506 is pegfilgrastim reported per 0.5 mg.
J2506 billing questions
Does J2506 include pegfilgrastim biosimilars?
No. J2506 is for pegfilgrastim excluding biosimilars; use the applicable HCPCS code for the specific biosimilar product.
How many units represent a 6 mg dose?
Each unit represents 0.5 mg, so 6 mg is 12 units. Report the amount administered.
Does J2506 include the injection administration?
No. J2506 represents the drug. A separately reportable administration service depends on how and where the injection is furnished.
How does Medicare treat J2506?
CMS assigns status E, excluding it from the physician fee schedule. When covered, it is a Part B drug generally priced through CMS quarterly ASP drug pricing files, and coverage is left to the Medicare contractor’s judgment.
What documentation supports J2506?
Document the non-biosimilar product furnished, the dose administered, and the clinical treatment context. The reported units should correspond to the administered dose in 0.5 mg increments.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J2506 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist